Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core

Based on the significant anti-inflammatory activity of natural quinone primin (5a), series of 1,4-benzoquinones, hydroquinones, and related resorcinols were designed, synthesized, characterized and tested for their ability to inhibit the activity of cyclooxygenase (COX-1 and COX-2) and 5-lipoxygenas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2020-10, Vol.204, p.112620-112620, Article 112620
Hauptverfasser: Sisa, Miroslav, Dvorakova, Marcela, Temml, Veronika, Jarosova, Veronika, Vanek, Tomas, Landa, Premysl
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 112620
container_issue
container_start_page 112620
container_title European journal of medicinal chemistry
container_volume 204
creator Sisa, Miroslav
Dvorakova, Marcela
Temml, Veronika
Jarosova, Veronika
Vanek, Tomas
Landa, Premysl
description Based on the significant anti-inflammatory activity of natural quinone primin (5a), series of 1,4-benzoquinones, hydroquinones, and related resorcinols were designed, synthesized, characterized and tested for their ability to inhibit the activity of cyclooxygenase (COX-1 and COX-2) and 5-lipoxygenase (5-LOX) enzymes. Structural modifications resulted in the identification of two compounds 5b (2-methoxy-6-undecyl-1,4-benzoquinone) and 6b (2-methoxy-6-undecyl-1,4-hydroquinone) as potent dual COX/5-LOX inhibitors. The IC50 values evaluated in vitro using enzymatic assay were for compound 5b IC50 = 1.07, 0.57, and 0.34 μM and for compound 6b IC50 = 1.07, 0.55, and 0.28 μM for COX-1, COX-2, and 5-LOX enzyme, respectively. In addition, compound 6d was identified as the most potent 5-LOX inhibitor (IC50 = 0.14 μM; reference inhibitor zileuton IC50 = 0.66 μM) from the tested compounds while its inhibitory potential against COX enzymes (IC50 = 2.65 and 2.71 μM for COX-1 and COX-2, respectively) was comparable with the reference inhibitor ibuprofen (IC50 = 4.50 and 2.46 μM, respectively). The most important structural modification leading to increased inhibitory activity towards both COXs and 5-LOX was the elongation of alkyl chain in position 6 from 5 to 11 carbons. Moreover, the monoacetylation in ortho position of bromo-hydroquinone 13 led to the discovery of potent (IC50 = 0.17 μM) 5-LOX inhibitor 17 (2-bromo-6-methoxy-1,4-benzoquinone) while bromination stabilized the hydroquinone form. Docking analysis revealed the interaction of compounds with Tyr355 and Arg120 in the catalytic site of COX enzymes, while the hydrophobic parts of the molecules filled the hydrophobic substrate channel leading up to Tyr385. In the allosteric catalytic site of 5-LOX, compounds bound to Tyr142 and formed aromatic interactions with Arg138. Taken together, we identified optimal alkyl chain length for dual COX/5-LOX inhibition and investigated other structural modifications influencing COX and 5-LOX inhibitory activity. [Display omitted] •Series of novel 1,4-benzoquinones, hydroquinones, and resorcinols were synthesized.•Compounds 5b and 6b possessed effective dual inhibition of COX-1, COX-2 and 5-LOX.•Most important modification was the elongation of alkyl chain from 5 to 11 carbons.•SAR study and docking revealed other modifications important for bioactivity.
doi_str_mv 10.1016/j.ejmech.2020.112620
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2429778252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523420305924</els_id><sourcerecordid>2429778252</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-ebc9b70ad6d7a2f2b5fbb7f87eff36b03d26cc456db2f89173d0f1d1cb8ee453</originalsourceid><addsrcrecordid>eNp9kEtP3DAUha2Kqkyn_QcIecmiGfxI7MwGCY1aWgmJRVmws2L7unOHTAx2QjX_voZAu-vqPnTOPbofISecrTjj6ny3gt0e3HYlmCgrLpRg78iCa9VWUjT1EVkwIWTVCFkfk4857xhjjWLsAzmWQsu25nJB0s_DMG4hY_5CcdiixTGmA-3ciE84lmbwZU8z9ugi9dHd4_CLxkD91PV0c3N33lTXN3f_vJn-xnFLHycc4gAv_gQ5JlfmnrqY4BN5H7o-w-fXuiS3377ebr6XO1c_NpfXlZNKjBVYt7aadV553YkgbBOs1aHVEIJUlkkvlHN1o7wVoV1zLT0L3HNnW4C6kUtyNp99SPFxgjyaPWYHfd8NEKdsRC3WWrei8FmSepa6FHNOEMxDwn2XDoYz8wzb7MwM2zzDNjPsYjt9TZjsHvxf0xvdIriYBVDefEJIJjuEwYHHBG40PuL_E_4AmBiTtQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2429778252</pqid></control><display><type>article</type><title>Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Sisa, Miroslav ; Dvorakova, Marcela ; Temml, Veronika ; Jarosova, Veronika ; Vanek, Tomas ; Landa, Premysl</creator><creatorcontrib>Sisa, Miroslav ; Dvorakova, Marcela ; Temml, Veronika ; Jarosova, Veronika ; Vanek, Tomas ; Landa, Premysl</creatorcontrib><description>Based on the significant anti-inflammatory activity of natural quinone primin (5a), series of 1,4-benzoquinones, hydroquinones, and related resorcinols were designed, synthesized, characterized and tested for their ability to inhibit the activity of cyclooxygenase (COX-1 and COX-2) and 5-lipoxygenase (5-LOX) enzymes. Structural modifications resulted in the identification of two compounds 5b (2-methoxy-6-undecyl-1,4-benzoquinone) and 6b (2-methoxy-6-undecyl-1,4-hydroquinone) as potent dual COX/5-LOX inhibitors. The IC50 values evaluated in vitro using enzymatic assay were for compound 5b IC50 = 1.07, 0.57, and 0.34 μM and for compound 6b IC50 = 1.07, 0.55, and 0.28 μM for COX-1, COX-2, and 5-LOX enzyme, respectively. In addition, compound 6d was identified as the most potent 5-LOX inhibitor (IC50 = 0.14 μM; reference inhibitor zileuton IC50 = 0.66 μM) from the tested compounds while its inhibitory potential against COX enzymes (IC50 = 2.65 and 2.71 μM for COX-1 and COX-2, respectively) was comparable with the reference inhibitor ibuprofen (IC50 = 4.50 and 2.46 μM, respectively). The most important structural modification leading to increased inhibitory activity towards both COXs and 5-LOX was the elongation of alkyl chain in position 6 from 5 to 11 carbons. Moreover, the monoacetylation in ortho position of bromo-hydroquinone 13 led to the discovery of potent (IC50 = 0.17 μM) 5-LOX inhibitor 17 (2-bromo-6-methoxy-1,4-benzoquinone) while bromination stabilized the hydroquinone form. Docking analysis revealed the interaction of compounds with Tyr355 and Arg120 in the catalytic site of COX enzymes, while the hydrophobic parts of the molecules filled the hydrophobic substrate channel leading up to Tyr385. In the allosteric catalytic site of 5-LOX, compounds bound to Tyr142 and formed aromatic interactions with Arg138. Taken together, we identified optimal alkyl chain length for dual COX/5-LOX inhibition and investigated other structural modifications influencing COX and 5-LOX inhibitory activity. [Display omitted] •Series of novel 1,4-benzoquinones, hydroquinones, and resorcinols were synthesized.•Compounds 5b and 6b possessed effective dual inhibition of COX-1, COX-2 and 5-LOX.•Most important modification was the elongation of alkyl chain from 5 to 11 carbons.•SAR study and docking revealed other modifications important for bioactivity.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2020.112620</identifier><identifier>PMID: 32738413</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>5-Lipoxygenase ; Anti-inflammatory activity ; Benzoquinones - chemistry ; Catalytic Domain ; Computer Simulation ; Cyclooxygenase ; Cyclooxygenase Inhibitors - chemical synthesis ; Cyclooxygenase Inhibitors - chemistry ; Cyclooxygenase Inhibitors - pharmacology ; Lipoxygenase Inhibitors - chemical synthesis ; Lipoxygenase Inhibitors - chemistry ; Lipoxygenase Inhibitors - pharmacology ; Molecular Docking Simulation ; Oxidation-Reduction ; Quinones ; Resorcinols ; Resorcinols - chemistry ; Spectrum Analysis - methods ; Structure-Activity Relationship</subject><ispartof>European journal of medicinal chemistry, 2020-10, Vol.204, p.112620-112620, Article 112620</ispartof><rights>2020 Elsevier Masson SAS</rights><rights>Copyright © 2020 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-ebc9b70ad6d7a2f2b5fbb7f87eff36b03d26cc456db2f89173d0f1d1cb8ee453</citedby><cites>FETCH-LOGICAL-c362t-ebc9b70ad6d7a2f2b5fbb7f87eff36b03d26cc456db2f89173d0f1d1cb8ee453</cites><orcidid>0000-0003-4960-2048 ; 0000-0001-5839-4450</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0223523420305924$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32738413$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sisa, Miroslav</creatorcontrib><creatorcontrib>Dvorakova, Marcela</creatorcontrib><creatorcontrib>Temml, Veronika</creatorcontrib><creatorcontrib>Jarosova, Veronika</creatorcontrib><creatorcontrib>Vanek, Tomas</creatorcontrib><creatorcontrib>Landa, Premysl</creatorcontrib><title>Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Based on the significant anti-inflammatory activity of natural quinone primin (5a), series of 1,4-benzoquinones, hydroquinones, and related resorcinols were designed, synthesized, characterized and tested for their ability to inhibit the activity of cyclooxygenase (COX-1 and COX-2) and 5-lipoxygenase (5-LOX) enzymes. Structural modifications resulted in the identification of two compounds 5b (2-methoxy-6-undecyl-1,4-benzoquinone) and 6b (2-methoxy-6-undecyl-1,4-hydroquinone) as potent dual COX/5-LOX inhibitors. The IC50 values evaluated in vitro using enzymatic assay were for compound 5b IC50 = 1.07, 0.57, and 0.34 μM and for compound 6b IC50 = 1.07, 0.55, and 0.28 μM for COX-1, COX-2, and 5-LOX enzyme, respectively. In addition, compound 6d was identified as the most potent 5-LOX inhibitor (IC50 = 0.14 μM; reference inhibitor zileuton IC50 = 0.66 μM) from the tested compounds while its inhibitory potential against COX enzymes (IC50 = 2.65 and 2.71 μM for COX-1 and COX-2, respectively) was comparable with the reference inhibitor ibuprofen (IC50 = 4.50 and 2.46 μM, respectively). The most important structural modification leading to increased inhibitory activity towards both COXs and 5-LOX was the elongation of alkyl chain in position 6 from 5 to 11 carbons. Moreover, the monoacetylation in ortho position of bromo-hydroquinone 13 led to the discovery of potent (IC50 = 0.17 μM) 5-LOX inhibitor 17 (2-bromo-6-methoxy-1,4-benzoquinone) while bromination stabilized the hydroquinone form. Docking analysis revealed the interaction of compounds with Tyr355 and Arg120 in the catalytic site of COX enzymes, while the hydrophobic parts of the molecules filled the hydrophobic substrate channel leading up to Tyr385. In the allosteric catalytic site of 5-LOX, compounds bound to Tyr142 and formed aromatic interactions with Arg138. Taken together, we identified optimal alkyl chain length for dual COX/5-LOX inhibition and investigated other structural modifications influencing COX and 5-LOX inhibitory activity. [Display omitted] •Series of novel 1,4-benzoquinones, hydroquinones, and resorcinols were synthesized.•Compounds 5b and 6b possessed effective dual inhibition of COX-1, COX-2 and 5-LOX.•Most important modification was the elongation of alkyl chain from 5 to 11 carbons.•SAR study and docking revealed other modifications important for bioactivity.</description><subject>5-Lipoxygenase</subject><subject>Anti-inflammatory activity</subject><subject>Benzoquinones - chemistry</subject><subject>Catalytic Domain</subject><subject>Computer Simulation</subject><subject>Cyclooxygenase</subject><subject>Cyclooxygenase Inhibitors - chemical synthesis</subject><subject>Cyclooxygenase Inhibitors - chemistry</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>Lipoxygenase Inhibitors - chemical synthesis</subject><subject>Lipoxygenase Inhibitors - chemistry</subject><subject>Lipoxygenase Inhibitors - pharmacology</subject><subject>Molecular Docking Simulation</subject><subject>Oxidation-Reduction</subject><subject>Quinones</subject><subject>Resorcinols</subject><subject>Resorcinols - chemistry</subject><subject>Spectrum Analysis - methods</subject><subject>Structure-Activity Relationship</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtP3DAUha2Kqkyn_QcIecmiGfxI7MwGCY1aWgmJRVmws2L7unOHTAx2QjX_voZAu-vqPnTOPbofISecrTjj6ny3gt0e3HYlmCgrLpRg78iCa9VWUjT1EVkwIWTVCFkfk4857xhjjWLsAzmWQsu25nJB0s_DMG4hY_5CcdiixTGmA-3ciE84lmbwZU8z9ugi9dHd4_CLxkD91PV0c3N33lTXN3f_vJn-xnFLHycc4gAv_gQ5JlfmnrqY4BN5H7o-w-fXuiS3377ebr6XO1c_NpfXlZNKjBVYt7aadV553YkgbBOs1aHVEIJUlkkvlHN1o7wVoV1zLT0L3HNnW4C6kUtyNp99SPFxgjyaPWYHfd8NEKdsRC3WWrei8FmSepa6FHNOEMxDwn2XDoYz8wzb7MwM2zzDNjPsYjt9TZjsHvxf0xvdIriYBVDefEJIJjuEwYHHBG40PuL_E_4AmBiTtQ</recordid><startdate>20201015</startdate><enddate>20201015</enddate><creator>Sisa, Miroslav</creator><creator>Dvorakova, Marcela</creator><creator>Temml, Veronika</creator><creator>Jarosova, Veronika</creator><creator>Vanek, Tomas</creator><creator>Landa, Premysl</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4960-2048</orcidid><orcidid>https://orcid.org/0000-0001-5839-4450</orcidid></search><sort><creationdate>20201015</creationdate><title>Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core</title><author>Sisa, Miroslav ; Dvorakova, Marcela ; Temml, Veronika ; Jarosova, Veronika ; Vanek, Tomas ; Landa, Premysl</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-ebc9b70ad6d7a2f2b5fbb7f87eff36b03d26cc456db2f89173d0f1d1cb8ee453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>5-Lipoxygenase</topic><topic>Anti-inflammatory activity</topic><topic>Benzoquinones - chemistry</topic><topic>Catalytic Domain</topic><topic>Computer Simulation</topic><topic>Cyclooxygenase</topic><topic>Cyclooxygenase Inhibitors - chemical synthesis</topic><topic>Cyclooxygenase Inhibitors - chemistry</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>Lipoxygenase Inhibitors - chemical synthesis</topic><topic>Lipoxygenase Inhibitors - chemistry</topic><topic>Lipoxygenase Inhibitors - pharmacology</topic><topic>Molecular Docking Simulation</topic><topic>Oxidation-Reduction</topic><topic>Quinones</topic><topic>Resorcinols</topic><topic>Resorcinols - chemistry</topic><topic>Spectrum Analysis - methods</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sisa, Miroslav</creatorcontrib><creatorcontrib>Dvorakova, Marcela</creatorcontrib><creatorcontrib>Temml, Veronika</creatorcontrib><creatorcontrib>Jarosova, Veronika</creatorcontrib><creatorcontrib>Vanek, Tomas</creatorcontrib><creatorcontrib>Landa, Premysl</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sisa, Miroslav</au><au>Dvorakova, Marcela</au><au>Temml, Veronika</au><au>Jarosova, Veronika</au><au>Vanek, Tomas</au><au>Landa, Premysl</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2020-10-15</date><risdate>2020</risdate><volume>204</volume><spage>112620</spage><epage>112620</epage><pages>112620-112620</pages><artnum>112620</artnum><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>Based on the significant anti-inflammatory activity of natural quinone primin (5a), series of 1,4-benzoquinones, hydroquinones, and related resorcinols were designed, synthesized, characterized and tested for their ability to inhibit the activity of cyclooxygenase (COX-1 and COX-2) and 5-lipoxygenase (5-LOX) enzymes. Structural modifications resulted in the identification of two compounds 5b (2-methoxy-6-undecyl-1,4-benzoquinone) and 6b (2-methoxy-6-undecyl-1,4-hydroquinone) as potent dual COX/5-LOX inhibitors. The IC50 values evaluated in vitro using enzymatic assay were for compound 5b IC50 = 1.07, 0.57, and 0.34 μM and for compound 6b IC50 = 1.07, 0.55, and 0.28 μM for COX-1, COX-2, and 5-LOX enzyme, respectively. In addition, compound 6d was identified as the most potent 5-LOX inhibitor (IC50 = 0.14 μM; reference inhibitor zileuton IC50 = 0.66 μM) from the tested compounds while its inhibitory potential against COX enzymes (IC50 = 2.65 and 2.71 μM for COX-1 and COX-2, respectively) was comparable with the reference inhibitor ibuprofen (IC50 = 4.50 and 2.46 μM, respectively). The most important structural modification leading to increased inhibitory activity towards both COXs and 5-LOX was the elongation of alkyl chain in position 6 from 5 to 11 carbons. Moreover, the monoacetylation in ortho position of bromo-hydroquinone 13 led to the discovery of potent (IC50 = 0.17 μM) 5-LOX inhibitor 17 (2-bromo-6-methoxy-1,4-benzoquinone) while bromination stabilized the hydroquinone form. Docking analysis revealed the interaction of compounds with Tyr355 and Arg120 in the catalytic site of COX enzymes, while the hydrophobic parts of the molecules filled the hydrophobic substrate channel leading up to Tyr385. In the allosteric catalytic site of 5-LOX, compounds bound to Tyr142 and formed aromatic interactions with Arg138. Taken together, we identified optimal alkyl chain length for dual COX/5-LOX inhibition and investigated other structural modifications influencing COX and 5-LOX inhibitory activity. [Display omitted] •Series of novel 1,4-benzoquinones, hydroquinones, and resorcinols were synthesized.•Compounds 5b and 6b possessed effective dual inhibition of COX-1, COX-2 and 5-LOX.•Most important modification was the elongation of alkyl chain from 5 to 11 carbons.•SAR study and docking revealed other modifications important for bioactivity.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>32738413</pmid><doi>10.1016/j.ejmech.2020.112620</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-4960-2048</orcidid><orcidid>https://orcid.org/0000-0001-5839-4450</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2020-10, Vol.204, p.112620-112620, Article 112620
issn 0223-5234
1768-3254
language eng
recordid cdi_proquest_miscellaneous_2429778252
source MEDLINE; Elsevier ScienceDirect Journals
subjects 5-Lipoxygenase
Anti-inflammatory activity
Benzoquinones - chemistry
Catalytic Domain
Computer Simulation
Cyclooxygenase
Cyclooxygenase Inhibitors - chemical synthesis
Cyclooxygenase Inhibitors - chemistry
Cyclooxygenase Inhibitors - pharmacology
Lipoxygenase Inhibitors - chemical synthesis
Lipoxygenase Inhibitors - chemistry
Lipoxygenase Inhibitors - pharmacology
Molecular Docking Simulation
Oxidation-Reduction
Quinones
Resorcinols
Resorcinols - chemistry
Spectrum Analysis - methods
Structure-Activity Relationship
title Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T09%3A21%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis,%20inhibitory%20activity%20and%20in%20silico%20docking%20of%20dual%20COX/5-LOX%20inhibitors%20with%20quinone%20and%20resorcinol%20core&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Sisa,%20Miroslav&rft.date=2020-10-15&rft.volume=204&rft.spage=112620&rft.epage=112620&rft.pages=112620-112620&rft.artnum=112620&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2020.112620&rft_dat=%3Cproquest_cross%3E2429778252%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2429778252&rft_id=info:pmid/32738413&rft_els_id=S0223523420305924&rfr_iscdi=true